Curated updates on drug launches, pricing changes, insurance coverage, shortages, and clinical trials.
This article from Eli Lilly Press Releases covers: FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water...
Read nowThis article from Eli Lilly Press Releases covers: Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S..
Read nowThis article from Eli Lilly Press Releases covers: Media Statement: Zepbound (tirzepatide) KwikPen now available at self-pay pricing at major pharmacies nationwide in addition to LillyDirect.
Read nowThis article from Endpoints News covers: Novo's double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheim.
Read nowThis article from Eli Lilly Press Releases covers: Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults...
Read nowThis article from STAT News covers: STAT+: Genetics may shape GLP-1 outcomes, slightly.
Read nowThis article from STAT News covers: STAT+: Pharmalittle: We’re reading about cheap generic obesity drugs in India, high demand for estrogen patches and more.
Read nowThis article from STAT News covers: STAT+: Pharmalittle: We’re reading about top pharma lobbyist stepping down, genes and GLP-1 drugs, and more.
Read nowThis article from Endpoints News covers: Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera option.
Read nowFoundayo launched at $149/month self-pay on April 9, 2026 — available the same day at retail pharmacies, through LillyDirect, and via telehealth providers including Ro, Amazon Pharmacy, and Weight Watchers Med+. If you've been sitting on the fence about starting a GLP-1, this is the most accessible on-ramp yet: no needles, no meal timing, 27.3 lbs average weight loss at the top dose, and the broadest same-day launch network of any GLP-1 to date.
Read nowThe FDA approved Foundayo (orforglipron) on April 1, 2026 — the first GLP-1 pill with no meal-timing rules — launching at $149/month self-pay, with a $25/month option for commercially insured patients. If you've been avoiding GLP-1s because of injection anxiety or high cost, this is the lowest barrier to entry yet: 27.3 lbs average weight loss at the top dose, no fasting required, and the broadest Medicare access pathway of any obesity drug currently on the market.
Read nowIndia's semaglutide patent expired March 20, 2026, and generic prices immediately crashed to roughly $14–15/month — while the same molecule costs over $1,000/month in the US. Generic semaglutide won't reach US pharmacies until 2033–2037 at the earliest, but Foundayo at $149/month self-pay and Zepbound's KwikPen at $299/month are the closest things to patent-cliff pricing available to you right now.
Read nowAs of April 10, 2026, the free Zepbound savings card — $299/month for the 2.5 mg starter dose, $449/month for maintenance — works at over 70,000 pharmacies including Walgreens, Kroger, Sam's Club, Amazon Pharmacy, and Publix. If you're paying $1,050+ retail for Zepbound at any of these chains right now, stop and enroll at zepbound.lilly.com/savings before your next refill — it takes minutes and saves you $600–$750/month.
Read nowPhase 3b data from TOGETHER-PsA, presented at AAD 2026 in Denver, showed Zepbound plus Taltz hit the combined ACR50 + 10% weight loss endpoint in 31.7% of psoriatic arthritis patients — versus 0.8% on Taltz alone. If you're on a biologic for PsA or psoriasis and have obesity, this peer-reviewed paper (published in *Arthritis & Rheumatology* March 2026) is now the document to bring your rheumatologist when requesting a Zepbound prior authorization.
Read nowA 27,885-person study published in *Nature* on April 8, 2026 confirmed your GLP1R gene variant can predict about 3.3 extra pounds of weight loss — real, but not enough to change what your doctor prescribes. Before spending $299/year on 23andMe Total Health expecting it to explain your GLP-1 results, know that dose, diet, and adherence still drive the outcome far more than genetics.
Read nowNovo Nordisk's 36-year GLP-1 pioneer Lotte Bjerre Knudsen retired in April 2026, the same week obesity specialist Sylvia Shubert moved to Boehringer Ingelheim as SVP of obesity and liver health. Neither departure affects what's in your pharmacy today — but Boehringer's Phase 3 survodutide data, expected H1 2026, could be your first look at a serious third competitor in the GLP-1 weight-loss space.
Read nowPhRMA CEO Steve Ubl announced he'll leave by end of 2026 — his successor inherits a drug class retailing above $1,000/month that costs $10–30 to manufacture, with a Medicare GLP-1 Bridge program launching July 2026 at $245/month. If you're on Medicare and use a GLP-1 for diabetes or cardiovascular risk, check CMS.gov starting July 1 — you may have a new, cheaper access pathway your plan hasn't told you about.
Read nowOn April 9, 2026, the EMA approved a Wegovy logistics update allowing delivery at up to 30°C for 48 hours — making it the first GLP-1 weight-loss drug in the EU cleared for standard parcel delivery without refrigerated transport. If a Wegovy pen arrives warm after a normal shipping delay, the drug's actual temperature tolerance is higher than most patients assume; your home storage rules haven't changed.
Read now